Nuvation Bio (NUVB) Revenue & Revenue Breakdown
Nuvation Bio Revenue Highlights
Latest Revenue (Y)
$7.87M
Latest Revenue (Q)
$4.83M
Main Segment (Y)
License Revenue
Main Geography (Y)
CHINA
Nuvation Bio Revenue by Period
Nuvation Bio Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $7.87M | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
Nuvation Bio generated $7.87M in revenue during NA 2024, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Nuvation Bio Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | $4.83M | 56.71% |
| 2025-03-31 | $3.08M | -46.00% |
| 2024-12-31 | $5.71M | 685.56% |
| 2024-09-30 | $727.00K | -49.34% |
| 2024-06-30 | $1.44M | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $264.00K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | - |
Nuvation Bio generated $4.83M in revenue during Q2 2025, up 56.71% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Nuvation Bio Revenue Breakdown
Nuvation Bio Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 |
|---|---|
| License Revenue | $2.09M |
Nuvation Bio's latest annual revenue breakdown by segment (product or service), as of Dec 24: License Revenue (100.00%).
Quarterly Revenue by Product
| Product/Service | Jun 25 | Mar 25 |
|---|---|---|
| License | $3.60M | - |
| Product | $1.24M | - |
| Product Revenue | - | $779.00K |
| Royalty Revenue | - | $249.00K |
Nuvation Bio's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: License (74.38%), and Product (25.62%).
Nuvation Bio Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 24 |
|---|---|
| CHINA | $5.20M |
| JAPAN | $2.70M |
Nuvation Bio's latest annual revenue breakdown by geography, as of Dec 24: CHINA (65.82%), and JAPAN (34.18%).
Quarterly Revenue by Country
| Country | Jun 25 | Mar 25 | Dec 24 | Sep 24 |
|---|---|---|---|---|
| CHINA | $3.40M | $2.90M | $5.10M | $100.00K |
| UNITED STATES | $1.24M | - | - | - |
| JAPAN | $241.00K | $200.00K | $2.10M | $600.00K |
Nuvation Bio's latest quarterly revenue breakdown by geography, as of Jun 25: CHINA (69.69%), UNITED STATES (25.37%), and JAPAN (4.94%).
Nuvation Bio Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| MAZE | Maze Therapeutics | $167.50M | - |
| WVE | Wave Life Sciences | $108.30M | $8.70M |
| AMLX | Amylyx Pharmaceuticals | $87.37M | - |
| IMNM | Immunome | $9.04M | $2.93M |
| NUVB | Nuvation Bio | $7.87M | $4.83M |
| DNTH | Dianthus Therapeutics | $6.24M | $1.16M |
| ATAI | Atai Life Sciences | - | $1.55M |
| ELVN | Enliven Therapeutics | - | - |
| SYRE | Spyre Therapeutics | - | - |
| TRML | Tourmaline Bio | - | - |
| ORIC | ORIC Pharmaceuticals | - | - |